| Literature DB >> 26887056 |
Zhi-Yan Hu1,2,3, Xiao-Yan Wang1,2,3, Wen-Bin Guo4,5,6, Lin-Ying Xie1,2,3, Yu-Qi Huang4, Yan-Ping Liu1,2,3, Li-Wei Xiao1,2,3, Sheng-Nan Li1,2,3, Hui-Fang Zhu1,2,3, Zu-Guo Li1,2,3, Heping Kan4.
Abstract
Our earlier findings indicate that the long non-coding RNA MALAT1 promotes colorectal cancer (CRC) cell proliferation, invasion and metastasis in vitro and in vivo by increasing expression of AKAP-9. In the present study, we investigated the molecular mechanism by which MALAT1 enhances AKAP9 expression in CRC SW480 cells. We found that MALAT1 interacts with both SRPK1 and SRSF1. MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation. Following MALAT1 knockdown, overexpression of SRPK1 was sufficient to restore SRSF1 phosphorylation and AKAP-9 expression to a level that promoted cell proliferation, invasion and migration in vitro. Conversely, SRPK1 knockdown after overexpression of MALAT1 in SW480 cells diminished SRSF1 phosphorylation and AKAP-9 expression and suppressed cell proliferation, invasion and migration in vitro. These findings suggest MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation in CRC cells. These results reveal a novel molecular mechanism by which MALAT1 regulates AKAP-9 expression in CRC cells.Entities:
Keywords: AKAP-9; MALAT-1; SRSF1; colorectal cancer; long non-coding RNA
Mesh:
Substances:
Year: 2016 PMID: 26887056 PMCID: PMC4905507 DOI: 10.18632/oncotarget.7367
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1MALAT1 interacts with SRPK1 and SRSF1 protein
(A) Immunoprecipitation from SW480 cells using SRSF1 antibody, mouse serum (negative control) or SNRNP70 (positive control), RT-PCR or qPCR from the IP samples using MALAT1-specific primers. Quantitative RT-PCR analysis of MALAT1 is expressed as fold enrichment over the IgG control. (B) Immunoprecipitation from SW480 cells using SRPK1 antibody mouse serum or SNRNP70 (positive control), RT-PCR or qPCR from the IP samples using MALAT1-specific primers. Quantitative RT-PCR analysis of MALAT1 is expressed as fold enrichment over the IgG control (C) SW480 cells were lysed and subjected to Co-IP with SRSF1 and SRPK1 antibody or mouse immunoglobulin G (IgG). Western blotting was performed to detect endogenous SRSF1 and SRPK1 in the precipitates (IP) or in cell lysates not subjected to IP (Input). (D) Intracellular localization of fluorescent-labeled SRPK1 and fluorescent-labeled SRSF1 by immunofluorescent staining. Immunofluorescent staining of SW480 cells treated with Alexa 488-labeled SRPK1 and Alexa 594-labeled SRSF1. Da: Nuclei were stained with DAPI (blue); Db: Alexa 488-labeled SRPK1 (green); Dc: Alexa 594-labeled SRSF1 (red); Dd: Superposition of Db and Dc demonstrated co-localization of SRPK1 and SRSF1 (yellow).
Figure 2MALAT1 enhances AKAP-9 expression by promoting SRPK1-mediated SRSF1 protein phospholation
(A) Immunostaining of phospholated SRSF1 protein in Scramble-SW480 RNAa-MALAT1-SW480 and RNAi-MALAT1-SW480 cells. Magnification: 1800x. (B) The phospholated SRSF1 protein in nucleus was detected by Western blot analysis using mAb1H4 antibody.(C) The phospholated SRSF1 protein levels were normalized to Histone. *P < 0.001 compared to the control group(Scramble), n = 3. (D) Immunostaining of SRPK1 protein in Scramble-SW480 RNAa-MALAT1-SW480 and RNAi-MALAT1-SW480 cells. Magnification: 1800x. (E) Western blot analysis of SRPK1 protein expression in Scramble-SW480 RNAa-MALAT1-SW480 and RNAi-MALAT1-SW480 cells. (F) The protein levels were normalized to α-Tubulin. *P < 0.05 compared to the control group (Scramble), n = 3. (G) RNAa-MALAT1-SW480 cells were treated with SRPK1 inhibitor SRPIN340 in different dose. (H) The protein levels were normalized to α-Tubulin. *P < 0.001 compared to the control group (Blank and dimethylsulphoxide 0.02%), n = 3.
Figure 3Overexpression of SRPK1 in MALAT1-deficient SW480 cells (RNAi-MALAT1) restored AKAP-9 expression by reversing the level of SRSF1 phosphorylation
(A) Overexpression of SRPK1 in RNAi-MALAT1 SW480 cells restored phospholated SRSF1 and AKAP-9 protein expression. (B) The phospholated SRSF1 and AKAP-9 protein levels were normalized to α-Tubulin, *P < 0.05 compared to the control group (Scramle-MALAT1), **P < 0.01 compared to the control group (RNAi-MALAT1/Vector), n = 3. (C) The phospholated SRSF1 protein in nucleus and cytoplasm were detected by Western blot analysis using mAb1H4 antibody respectively. The phospholated SRSF1 protein is enriched in nucleus. (D) The phospholated SRSF1 protein levels were normalized to Histone. *P < 0.05 compared to the control group (Scramle-MALAT1), **P < 0.01 compared to the control group (RNAi-MALAT1/Vector), n = 3.
Figure 4Overexpression of SRPK1 in MALAT1-deficient (RNAi-MALAT1) SW480 cells restored cell proliferation, migration and invasion inhibited by MALAT1 knockdown
(A) Overexpression of SRPK1 in RNAi-MALAT1 SW480 cells restored cell proliferation inhibited by MALAT1 knockdown as measured by CCK8 assay. *P < 0.05 compared to the control group (Scramle-MALAT1); **P < 0.05 compared to the control group (RNAi-MALAT1/Vector) in Day (3) and Day (4), n = 3. (B–C) Cell migration was measured by both the wound-healing assay (B) and transwell migration assay (C). Overexpression of SRPK1 in RNAi-MALAT1 SW480 cells markedly restored the cells migration. *P < 0.001 compared to the control group (Scramle-MALAT1); **P < 0.05 compared to the control group (RNAi-MALAT1/Vector), n = 3. (D) Overexpression of SRPK1 in RNAi-MALAT1 SW480 cells restored cells invasion. The invasive capability was determined using matrigel invasion chambers. *P < 0.001 compared to the control group (Scramle-MALAT1); **P < 0.001 compared to the control group (RNAi-MALAT1/Vector), n = 3.
Figure 5Knockdown of SRPK1 in MALAT1-activated SW480 cells (RNAa-MALAT1) attenuated AKAP-9 expression by attenuating the level of SRSF1 phosphorylation
(A) Knockdown of SRPK1 in RNAa-MALAT1 SW480 cells attenuated phospholated SRSF1 and AKAP-9 protein expression. (B) The phospholated SRSF1 and AKAP-9 protein levels were normalized α-Tubulin. *P < 0.01 compared to the control group (Scramle-MALAT1), **P < 0.01 compared to the control group (RNAa-MALAT1/siCtrl), n = 3. (C) The phospholated SRSF1 protein in nucleus and cytoplasm were detected by Western blot analysis using mAb1H4 antibody respectively. The phospholated SRSF1 protein is enriched in nucleus. (D) The phospholated SRSF1 protein levels were normalized to Histone. *P < 0.05 compared to the control group (Scramle-MALAT1), **P < 0.01 compared to the control group (RNAa-MALAT1/siCtrl), n = 3.
Figure 6Knockdown of SRPK1 in MALAT1-activated (RNAa-MALAT1) SW480 cells attenuated cell proliferation, migration and invasion induced by MALAT1 overexpression
(A) Knockdown of SRPK1 attenuated cell proliferation induced by MALAT1 overexpression as measured by CCK8 assay. *P < 0.05 compared to the control group (Scramle-MALAT1); **P < 0.05 compared to the control group (RNAa-MALAT1/siCtrl)) in Day (3) and Day (4), n = 3. (B–C) Cell migration was measured by both the wound-healing assay (B) and transwell migration assay (C). Knockdown of SRPK1 in RNAa-MALAT1 SW480 cells markedly attenuated the cells migration. *P < 0.01 compared to the control group (Scramble-MALAT1); **P < 0.01 compared to the control group (RNAa-MALAT1/siCtrl) in (B) and (C), n = 3. (D) Knockdown of SRPK1 in RNAa-MALAT1 SW480 cells inhibited cells invasion. The invasive capability was determined using matrigel invasion chambers. *P < 0.001 compared to the control group (Scramble-MALAT1); **P < 0.001 compared to the control group (RNAa-MALAT1/siCtrl), n = 3.